Investigating the effect of technetium[99Tc]methylenediphosphonate injection in the treatment of type 2 diabetes mellitus combined with osteoporosis and its influence on patients' cardiac function
Objective To explore the effect of technetium[99Tc]methylenediphosphonate injection in the treatment of type 2 diabetes mellitus combined with osteoporosis and its influence on patients' cardiac function. Methods A total of 80 patients with type 2 diabetes mellitus complicated with osteoporosis were selected as the study subjects and divided into a control group and an observation group by random numerical table,with 40 cases in each group. The control group was treated with metformin combined with alfacalcitol tablets,and the observation group was treated with technetium[99Tc]methylenediphosphonate injection. The treatment effect,symptom improvement effect,bone mineral density,cardiac function indicators and the occurrence of adverse reactions were compared between the two groups. Results The total effective rate of treatment in the observation group was 95.00％,which was higher than 75.00％ in the control group (P<0.05). After treatment,the duration of morning stiffness in both groups was shorter than that before treatment,and the scores of joint swelling and joint tenderness were lower than those before treatment;the duration of morning stiffness of (22.15±0.16) min in the observation group was shorter than (26.69±0.19) min in the control group;the scores of joint swelling and joint tenderness were (1.21±0.22) and (1.21±0.21) points in the observation group,which were lower than (1.59±0.26) and (2.34±0.25) points in the control group (P<0.05). After treatment,the bone density of Ward's triangle of hip and L2-4 in both groups was higher than that before treatment;the bone density of Ward's triangle of hip and L2-4 were (0.69±0.11) g/cm2 and (0.76±0.11) g/cm2 in the observation group,which were higher than (0.62±0.13) and (0.70±0.13) g/cm2 in the control group (P<0.05). After treatment,the aspartate aminotransferase (AST),lactate dehydrogenase (LDH),and B-type natriuretic peptide (BNP) in both groups were lower than those before treatment;the observation group had AST of (39.05±1.65) U/L,LDH of (354.54±10.21) U/L,and BNP of (100.65±8.65) pg/ml,which were lower than (41.05±1.06) U/L,(379.48±10.16) U/L,and (104.58±8.49) pg/ml in the control group (P<0.05). The incidence of adverse reactions of the observation group was 5.00％,which had no statistical difference compared with 10.00％ in the control group (P>0.05). Conclusion Technetium[99Tc]methylenediphosphonate injection has ideal efficacy in the treatment of type 2 diabetes mellitus combined with osteoporosis,which can better regulate the body's bone metabolism,improve bone density,and protect the cardiac function.
Type 2 diabetes mellitusOsteoporosisCardiac functionTechnetium[99Tc]methylenediphosphonate injectionBone densityBone metabolismCurative effect
万方数据
